breast reduction consultation
Breast Cancer Treatment with Femara
In accordance with the cancer incidents survey, there are more than 215,000 women have been diagnosed as breast cancer patients each year. Basically, the breast cancer patients are not only given the surgical treatment, sometimes they must undergo chemotherapy or radiotherapy to fully eliminate the cancer. At the same time, they might need to consider whether to take the adjuvant treatment or not to effectively lessen the risk of the recurrence of breast cancer. You might wish to know more about Cancer Research and Breast Cancer Series Introduction too.
Whenever a woman's breast cancer does come back or spreads to other parts of the body, she may be at greater risk of dying from the disease. Women whose breast cancer is observed in the nearby lymph nodes at diagnosis and people who receive chemotherapy after surgery are thought to be at higher risk for breast cancer recurrence.
Postmenopausal women whose early-stage breast cancer is hormone-sensitive have a new choice as their first hormone therapy following surgery. The U.S. Food and Drug Administration lately approved Femara (letrozole tablets) on December 28, 2005 for this kind of use. This acceptance was based upon a median of 24 months of therapy. The investigation is still ongoing to discover the long-term safety and efficiency of Femara. Already a leading breast cancer treatment, Femara has become the only medicine in a group called aromatase inhibitors which is approved to be used both right after surgical procedure and after 5 years of tamoxifen. The FDA issued Femara a high priority evaluation, a distinction reserved for medications that could probably offer a considerable improvement when compared to products at the moment on the market.
A panel from the American Society of Clinical Oncology, the country's major group of oncologists, recommends aromatase inhibitors, including Femara, be part of the optimal adjuvant treatment for this group of women.
"One of the greatest fears confronted by women who are medicated for early breast cancer is that their cancer will come back. With Femara, we certainly have a possibility that will help address that fear early on, even in patients who we know encounter the highest risk of recurrence," said Matthew Ellis, MD, PhD, FRCP, director of the Breast Cancer Program at Washington University in St. Louis.
In a large clinical study of post-surgery breast cancer therapy, scientists compared the potency of Femara and tamoxifen, some other drug prescribed after surgery. An analysis carried out after 26 months demonstrated that Femara lowered the risk of breast cancer coming back by 21% over the reduction offered by tamoxifen. Patients taking Femara also showed a 27 percent decrease in the risk of the cancer dispersing to distant parts of the body.
In this study, women at increased risk of recurrence experienced the greatest benefit from Femara. Femara decreased this risk by twenty nine percent in women whose breast cancer had already metastasize to the lymph nodes during the time of diagnosis and by 30 percent in women who had prior chemotherapy. The outcomes also showed that during these high-risk women, Femara lessened the potential risk of cancer spreading to distant parts of the body by 33 percent and 31 percent, respectively.
From the research above, we can see that the Femara treatment will not induce any bad effect to the patients. The side effects such as joint pain, weight gain and so on are really scary.
So, we hope that Femara is most likely the option for us to stop the breast cancer recurrence. The secondary cancer is much more dangerous than the primary cancer.
Breast Reduction Surgery Consultation Sydney
